drugset / Trial / NCT02622763

Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment

NCT02622763

Phase 1 Terminated 3 enrolled Fundacion Clinic per a la Recerca Biomédica
RandomizedParallel-groupSingle-blindOther

Summary

Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment.

Timeline

Start
2015-11
Primary completion
2019-05-05
Completion
2019-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject tolerogenic dendritic cells Cell therapy 1e+07 cells Other
Subject tolerogenic dendritic cells Cell therapy 1e+08 cells Other

Indications